Official Title
From Mouse to Man: Translating Findings in Mouse Study Into a Human Cohort (Luxembourgish Fiber Cohort: Lux-FiCo)
Brief Title
Luxembourgish Fiber Cohort
Protocol ID
NCT04352231
Lead Sponsor
Luxembourg Institute of Health
Brief Summary
Many human populations across the world are deficient in the intake of dietary fiber.
This decline in fiber consumption parallels an increase in prevalence of a multitude of
diseases (e.g. colorectal cancer, multiple sclerosis). A possible link for this
association between dietary changes and the diseases could rest in the trillions of
commensal gut microbes that digest dietary fibers, provide energy for colonic cells, and
modulate the immune system. However, the molecular mechanisms that link fiber deficiency
via the activities of the gut microbiome to various diseases have been poorly understood.
The investigators previously showed that, in a mouse model with a defined human gut
microbiota, removal of fiber from the diet favors proliferation of bacteria that degrade
the gut's protective mucus lining. In the proposed project, the investigators aim to
translate our findings from mouse studies to humans using a 2x2 crossover study among
healthy adults. Forty participants will be randomly assigned to a low- or high-fiber
dietary intervention and then, following a washout period to reverse any changes,
switched to the other diet type. By employing longitudinal sampling of stool collections,
the investigators envision that participants will exhibit increased abundance and
activities of mucolytic bacteria when fed a low-fiber diet. The unique selling point of
the proposed study involves setting up high-throughput culture collections of
mucus-degrading bacteria, whose abundances and activities will be investigated by
sequencing and enzymatic assays in stool. Additionally, the investigators will measure
inflammatory markers in blood using CyTOF to assess whether short-term fiber deficiency
exerts detectable changes in the host immune function. Thus, the proposed dietary
intervention clinical trial will help elucidate the role of fiber deficiency in various
chronic diseases.
Detailed Description
Industrialized nations tend to consume less dietary fiber and, in many nations with a
Western-style diet, average consumption is half the recommended daily intake of 25-38
g/day. Dietary fiber is an important component of a healthy diet because it increases
fecal bulking and laxation, lowers cholesterol and regulates levels of blood glucose. The
connection between low fiber-intake and disease may rest with the gut microbiota, the
trillions of commensal microorganisms that inhabit the gastrointestinal tract. Bacteria
found in the gut are responsible for an array of functions that support human health,
including conversion of host-indigestible fibers into short chain fatty acids (SCFAs),
which provide energy for colonic cells, support mucus production, and modulate the immune
system.
The investigators have recently investigated the effects of a fiber-free diet in a
gnotobiotic mouse model with a 14-member synthetic microbial community showing that
mucus-degrading bacteria outcompete fiber-degrading bacteria, causing degradation of the
colonic mucus layer. One member of this synthetic community, Akkermansia muciniphila, is
a commensal bacterium found at 1-4% relative abundance in the human gut and feeds
specifically on the host-secreted mucins. However, this bacterium is significantly
enriched in the gut of patients with multiple sclerosis and colorectal cancer, suggesting
that its mucolytic capabilities may play a role in these diseases. A microbial shift
toward enrichment of mucolytic bacteria could be an important precursor to gut-linked
diseases. While observational studies have identified a lower risk of irritable bowel
diseases (IBD) in people who consume diets high in fiber, fruits, and vegetables, no
study has explicitly investigated the effects of fiber on the functional capacity of the
human gut microbiome in the context of effects on the mucus-degrading microbiome. Based
on our published work in mice, for the current project, the investigators hypothesize
that deficiency of dietary fiber in humans promotes increased activities of
mucus-degrading bacteria, thereby reducing the mucus lining in the intestine. The
investigators request pump priming to initiate this pilot project, as it will generate
foundational datasets to inform numerous follow-up studies.
Thus, the current project seeks to translate findings from mouse models to humans, using
a crossover study among healthy adults. Participants will be randomly assigned to a first
dietary intervention that is low or high in fiber and then, following a washout period
intended to reverse any compositional changes, switched to the second diet type. The
diets will be evaluated by a nutritionist to ensure that they differ in fiber content,
but are comparable in terms of caloric and macronutrient content. The targeted amount of
dietary fiber intake from the high-fiber test meals will be around 30 g/d more than the
low-fiber diet. In addition to dietary records, the investigators will administer
questionnaires, obtain basic clinical measures (blood pressure, weight, height,
waist/thigh circumference), collect blood samples for immunological assays and collect
stool samples before and at the end of each diet intervention for sequencing and
functional profiling of bacterial communities.
The investigators will recruit healthy volunteers to participate in a 2x2 crossover
design controlled-diet study. After statistical consultation, the investigators conclude
that the investigators require a sample size of n=15 in each sequence group (a total
sample size of N=30) to have 87.5% power to detect a -0.5 difference in means for alpha
diversity (Shannon index) under the two diet conditions. Volunteers who meet all
inclusion and exclusion criteria will be randomly assigned to a high- or low-fiber diet
intervention and then, after a week-long washout period, will receive the second diet
type. High and low fiber meals containing a variety of fiber types will be served to
participants at a designated drop-off site (home or workplace) for one week in order to
decrease variance in fiber intake, increase adherence to the diet, and maximize knowledge
of the nutritional content in participants' diet. Nutritionally balanced dietary
interventions are designed by a qualified dietitian at SERVIOR in conjunction with the
LIH study team and delivered by Paul Eischen Traiteur, a partner catering service.
Participants on both diet interventions will be given multivitamin supplements in order
to further ensure they receive essential vitamins and minerals.
At the baseline visit, our team will work with nurses from the Clinical and
Epidemiological Investigation Center (CIEC, headed by Dr. Manon Gantenbein) to collect
demographic data, anthropometry, early life history, family medical history, detailed
dietary patterns, and biological samples (blood, urine, and stool). Participants will use
a Participant Diary to log their diet throughout the study in the form of daily 24 hour
food recalls, except for foods or beverages provided during the dietary interventions.
After each intervention period, a week-long washout period will be employed to reverse
any changes that occurred due to the diet.
Mid-way through each intervention and washout period, the investigators will administer a
brief survey containing questions relevant to our research objective. At each of these
visits, CIEC nurses will collect biological samples and anthropometric measures.
Participants will also be asked to drop off a stool sample for the next two days. All
participant data will be pseudonymized when exported from Research Electronic Data
Capture application (REDCap) for analysis and will be handled in accordance with the
General Data Protection Regulation (GDPR). The study has been granted ethical approval by
the Luxembourg Ministry of Health (Ref# 835x38895) and by Comité National d'Ethique de
Recherche (CNER; Ref# 201911/03).
Study Period
-
Enrollment Count
30 participants
Eligibility Criteria
Inclusion Criteria:
1. Male or female:
a. The investigators will aim for a 50:50 male:female ratio, at most 40:60.
Therefore, given a sample size of N=40, if 24 eligible participants are exceed for
one gender, the investigators will proceed with recruitment only for members of the
underrepresented gender.
2. Between 18 and 35 years of age (expand to 55 if needed)
3. BMI between 18.5 ≥ BMI > 25 kg/m2 (expand to 30 if needed)
4. Born in Europe
5. Current resident of Luxembourg City or Esch-sur-Alzette (expand to nearby communes
if needed)
6. Own a smartphone with access to Android or Apple Store applications
Exclusion Criteria:
1. Following a specific diet or subject to dietary restrictions for any reason
2. "Vigorous" physical activity level based on the International Physical Activity
Questionnaire - Short Form (IPAQ-SF) criteria
3. Antibiotics usage within the past 3 months
4. Probiotics usage within the past 1 month
5. Laxatives usage within the past 1 month
6. Other regular medication usage (e.g. ibuprofen, warfarin)
7. Current or former smoker
8. Gastrointestinal disorder (e.g. ulcerative colitis, Crohn's disease) diagnosis
9. History of gastrointestinal surgery (excluding appendectomy)
10. Metabolic disorder diagnosis or predisposition (determined by blood test at
eligibility screen)
1. Prediabetes: fasting glucose 100-125 mg/dL (6.1-7.0 mmol/L) and/or drug
treatment of elevated glucose (8)
2. Diabetes: fasting glucose ≥126 mg/dL (7.0 mmol/L) and/or drug treatment of
elevated glucose and/or previously diagnosed type 1 or type 2 diabetes (8)
3. Hypertriglyceridaemia: fasting triglycerides ≥1.7 mmol/L (≥150 mg/dL) and/or
drug treatment for elevated triglycerides (9)
4. Hypercholesterolaemia: Fasting High-density lipoprotein cholesterol (HDL-C) <
40 mg/dL (< 1.0 mmol/L) in men and < 45 mg/dL (< 1.2mmol/L) in women and/or
drug treatment for reduced HDL-C (9)
5. Hypertension: Systolic BP ≥130 and/or diastolic BP ≥80 mm Hg and/or drug
treatment of previously diagnosed hypertension (10)
11. Cancer (any type) diagnosis (note that a history of cancer that has been in
remission for >3 years may still be considered eligible)
12. Immunodeficiency disorder (e.g. HIV) or autoimmune disorder (e.g. rheumatoid
arthritis, lupus) diagnosis
13. Neurological disorder (e.g. advanced dementia, diagnosed major depressive disorder
or generalized anxiety disorder)
14. Coagulation problems (e.g. hemophilia) or anemia impacting ability to participate in
blood draw
15. Circulatory disorder (e.g. ischemic heart diseases or history of stroke)
16. Currently pregnant or lactating (breastfeeding)
17. Vacation planned during study period
18. Moving out of Luxembourg during the study period
19. Potential conflict of interest: involved in study design, administration, data
analysis, or publication of findings or belonging to the lab group of the study's
principal investigators
Filters
Dietary Fiber
Gastrointestinal Microbiome
Healthy Volunteers
NA
COMPLETED
ADULT